exRNAdisease

Entry Detail

---



General Information

Database ID: exR0089284 RNA Name: hsa-miR-654-5p RNA Type: miRNA Chromosome: chr14 Starnd: + Coordinate: Start Site(bp): 101040234 End Site(bp): 101040255 External Links: hsa-miR-654-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand BCL9L chr11 118893875 118925608 - ATP11A chr13 112690329 112887168 + PHB chr17 49404049 49414905 - ZDHHC3 chr3 44915257 44976185 - PKM chr15 72199029 72231822 - ATXN7L3 chr17 44191805 44200113 - SH3PXD2A chr10 103594027 103855543 - ITGA5 chr12 54395261 54419266 - TP53 chr17 7661779 7687550 - CBFA2T3 chr16 88874858 88977207 - CS chr12 56271699 56300391 - LY6E chr8 143017982 143023832 + SPINT1 chr15 40844018 40858207 + AGTRAP chr1 11736084 11754802 + URM1 chr9 128371361 128392016 + BCL7A chr12 122019422 122062044 + MEF2D chr1 156463727 156500779 - DHCR24 chr1 54849627 54887195 - JADE2 chr5 134524312 134583230 + LSM12 chr17 44034328 44067619 - ZMIZ1 chr10 79068966 79316528 + TOB2 chr22 41433494 41446801 - ACTN4 chr19 38647649 38731589 + XPO6 chr16 28097979 28211920 - KMT2D chr12 49018975 49059774 - SMAD3 chr15 67063763 67195169 + BCAM chr19 44809071 44821421 + IGF2BP1 chr17 48997385 49056145 + GID4 chr17 18039408 18068405 + NID1 chr1 235975830 236065109 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000417 chr12 69644908 69656342 + hsa_circ_0000642 chr15 80390757 80415142 + hsa_circ_0000816 chr17 80521229 80526077 + hsa_circ_0000643 chr15 80412669 80415142 + hsa_circ_0000943 chr19 47421744 47440665 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC239868.1 chr1 149861271 149862504 + AL035458.2 chr20 34234840 34281173 - AL356488.2 chr1 109100193 109100619 + NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - OIP5-AS1 chr15 41283990 41309737 + STAG3L5P-PVRIG2P-PILRB chr7 100336104 100367831 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.